Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 5024Carcinoma, Renal Cell 1577Urinary Bladder Neoplasms 1279Kidney Neoplasms 724Breast Neoplasms 643Neoplasms 630Carcinoma, Transitional Cell 490Carcinoma, Non-Small-Cell Lung 469Neoplasm Metastasis 468Melanoma 422Ovarian Neoplasms 401Colorectal Neoplasms 373Lung Neoplasms 333Pancreatic Neoplasms 262Sarcoma 233Stomach Neoplasms 227Uterine Cervical Neoplasms 225Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 215Head and Neck Neoplasms 192Squamous Cell Carcinoma of Head and Neck 189Colonic Neoplasms 167Carcinoma, Hepatocellular 167Esophageal Neoplasms 165Endometrial Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

cediranib 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Advanced Prostate Adenocarcinoma × Genitourinary × Clear all
NCT04914195 2023-08-01

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Bharat Serums and Vaccines Limited

Phase 3 Completed
155 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

NCT04843319 2023-05-19

VERU-100

Veru Inc.

Phase 1/2 Terminated
24 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

NCT00502164 2011-01-21

AZD2171IL/0003

AstraZeneca

Phase 1 Completed
40 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡